The news from phase 3 trials of psoriatic arthritis treatments is upbeat: certolizumab pegol (Cimzia), apremilast (Otezla), and secukinumab (Cosentyx) all continue to show positive effects.
Should you immunize your patients with rheumatoid arthritis against viral infections that could pose a danger to their health?
Patients with psoriatic arthritis achieve significant improvements in signs and symptoms with the interleukin-12/23 inhibitor ustekinumab (Stelara), and they maintain those gains for 2 years, according to final results from 3 major clinical trials.
A rheumatologist picks 5 studies he found particularly noteworthy at EULAR and gets right to the point about their potential clinical implications.
There’s an app in development that could make it easier -- even fun-- for young children with juvenile idiopathic arthritis to describe where and how much they hurt.
The first study to assess the effects of DMARDs or anti-TNF treatment in a real world population of patients with inflammatory arthritis shows a clinically significant improvement in work disability, productivity loss, and disease activity-- especially in those receiving TNF-α blockers.
Blisibimod, an experimental drug that inhibits autoimmune B-cell activation and survival, produced clinically important improvements in disease activity in systemic lupus erythematosus, as well as in fatigue, in a phase 2b clinical trial.
Ultrasound diagnosis of tenosynovitis has now been shown to be superior to clinical signs and symptoms (eg, early morning stiffness, symmetrical arthritis, and hand joint arthritis) in predicting early rheumatoid arthritis.
There is no generally accepted definition for remission of SLE. An international expert panel has provided a framework for testing individual definitions and issued 8 key statements regarding remission.
New guidelines issued at EULAR 2015 outline ways to reduce risks of complications for pregnant women with SLE and antiphospholipid syndrome. Details here.